AFT Pharmaceuticals has reported
its first annual result since being
publicly listed (PD 11 Dec 2015),
with revenue up 14% to $64m and
an $8.9m loss for the year to 31 Mar.The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 26 May 16 To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 May 16
CONSUMERS and health professionals are advised that Biogen Australia, in consultation with the Therapeutic Goods Administration (TGA), will withdraw multiple sclerosis therapy Zinbryta (daclizumab) from the Australian market following a review of cases of serious inflammatory brain disorders in Europe (PD 05 Mar).